By Robert Preidt HealthDay Reporter
MONDAY, Could 16, 2022 (HealthDay Information) — As america mourns a million deaths from COVID-19, a brand new examine signifies the grim tally might have been worse. Use of the Pfizer-BioNTech COVID-19 vaccine prevented greater than 110,000 deaths and 690,000 hospitalizations in america in 2021, researchers report.
The vaccine additionally prevented 8.7 million symptomatic circumstances of an infection and saved greater than $30 billion in well being care prices and greater than $40 billion in misplaced productiveness, the examine authors famous.
“The analyses present that the Pfizer-BioNTech COVID-19 vaccine contributed substantial public well being affect within the U.S. in 2021, and had a deep impact on the trajectory of the pandemic,” stated Manuela Di Fusco, of Pfizer’s well being economics and outcomes analysis group.
The Pfizer vaccine was the primary COVID-19 shot out there in america. It was given to just about six in 10 individuals nationwide who have been absolutely vaccinated in 2021, in accordance with the U.S. Facilities for Illness Management and Prevention.
The findings have been revealed on-line Could 15 within the Journal of Medical Economics. The entire examine authors obtained funding from Pfizer both as workers, consultants or workers of corporations paid by Pfizer.
Regardless of using COVID-19 vaccines, the U.S. loss of life toll through the pandemic neared a million final week.
President Joe Biden ordered U.S. flags flown at half-staff Thursday.
“We should stay vigilant in opposition to this pandemic and do every part we are able to to save lots of as many lives as potential,” Biden stated.
On this examine, researchers estimated the affect of the Pfizer vaccine utilizing a mannequin, real-world information and scientific trial information.
The mannequin used information on the variety of individuals vaccinated, the effectiveness of the vaccine in varied age teams, and the possibilities of being contaminated, creating signs and being hospitalized.
It additionally included the results of lengthy COVID, the variety of working days probably misplaced as a consequence of short-term sickness and the financial affect of untimely deaths from the illness.
The mannequin didn’t embrace the affect of the extra transmissible Omicron variant that turned the dominant coronavirus pressure on the finish of the examine interval.
The vaccine “was estimated to forestall thousands and thousands of COVID-19 symptomatic circumstances, hundreds of hospitalizations and deaths, and generated billions in societal financial worth within the U.S. in 2021,” Di Fusco stated in a journal information launch.
The findings “spotlight the chance to proceed widespread vaccination uptake to forestall COVID-19-related illness and generate societal advantages,” she added.
Quite a few limitations might have resulted within the numbers within the examine being underestimates, in accordance with Di Fusco and colleagues. These embrace not factoring within the vaccine’s potential to scale back transmission of the coronavirus, the severity of circumstances and the general affect of lengthy COVID .
The researchers additionally famous that their findings cannot be utilized to different COVID-19 vaccines or teams of individuals not particularly analyzed within the examine.
There’s extra on COVID-19 vaccines on the U.S. Facilities for Illness Management and Prevention.
SOURCE: Journal of Medical Economics, information launch, Could 16, 2022